Role of Local Therapy for Metastatic Gastrointestinal Malignancies

Abstract

Oligometastatic disease is an increasingly recognized intermediate tumor state between locally confined and widely metastatic cancer. Oligometastatic gastrointestinal (GI) malignancies represent a heterogeneous spectrum of disease, and treatment strategies are tailored to each patient and are impacted by multiple factors. Recent advances in systemic therapies, imaging techniques, and local treatment modalities have revolutionized cancer treatment and present new opportunities to improve outcomes in patients with a limited burden of metastatic disease. However, there is currently a lack of consensus and robust literature to guide patient selection and treatment strategies, including the optimal role and timing of local therapies as adjuncts to standard-of-care systemic therapy. The intent of this review is to comprehensively discuss the role of local therapies in the modern management of oligometastatic GI malignancies.

Keywords

oligometastatic - radiotherapy - stereotactic - SBRT - oligometastases

Publikationsverlauf

Eingereicht: 30. September 2024

Angenommen: 07. November 2024

Artikel online veröffentlicht:
04. Dezember 2024

• References

• 1 Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol 1995; 13 (01) 8-10
• 2 Palma DA, Olson R, Harrow S. et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet 2019; 393 (10185): 2051-2058
• 3 Palma DA, Olson R, Harrow S. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET Phase II Randomized Trial. J Clin Oncol 2020; 38 (25) 2830-2838
• 4 Howlader N, Noone AM, Krapcho M. et al. SEER Cancer Statistics Review, 1975–2017. SEER. April 2020 . Accessed September 10, 2024 at: https://seer.cancer.gov/csr/1975_2017/index.html
• 5 Sun JM, Shen L, Shah MA. et al; KEYNOTE-590 Investigators. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 2021; 398 (10302): 759-771
• 6 Doki Y, Ajani JA, Kato K. et al; CheckMate 648 Trial Investigators. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med 2022; 386 (05) 449-462
• 7 Bang YJ, Van Cutsem E, Feyereislova A. et al; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376 (9742) 687-697
• 8 Janjigian YY, Kawazoe A, Yañez P. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021; 600 (7890) 727-730
• 9 Janjigian YY, Shitara K, Moehler M. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 2021; 398 (10294): 27-40
• 10 Kroese TE, Christ SM, van Rossum PSN. et al. Incidence and survival of patients with oligometastatic esophagogastric cancer: a multicenter cohort study. Radiother Oncol 2022; 173: 269-276
• 11 Quint LE, Hepburn LM, Francis IR, Whyte RI, Orringer MB. Incidence and distribution of distant metastases from newly diagnosed esophageal carcinoma. Cancer 1995; 76 (07) 1120-1125
• 12 Kroese TE, van Laarhoven HWM, Schoppman SF. et al; OMEC Collaborators. Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: a Delphi consensus study in Europe. Eur J Cancer 2023; 185: 28-39
• 13 Kroese TE, van Rossum PSN, Nilsson M. et al; OMEC-Working Group (Supplementary File 1). Study protocol for the OligoMetastatic Esophagogastric Cancer (OMEC) project: a multidisciplinary European consensus project on the definition and treatment for oligometastatic esophagogastric cancer. Eur J Surg Oncol 2023; 49 (01) 21-28
• 14 Kroese TE, Bronzwaer S, van Rossum PSN. et al; OMEC Collaborators. European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4). Eur J Cancer 2024; 204: 114062
• 15 Ohtsu A, Boku N, Muro K. et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 1999; 17 (09) 2915-2921
• 16 Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 2004; 34 (10) 615-619
• 17 Shinoda M, Ando N, Kato K. et al; Japan Clinical Oncology Group. Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 2015; 106 (04) 407-412
• 18 Shi Z, Zhu X, Ke S. et al. Survival impact of concurrent chemoradiotherapy for elderly patients with synchronous oligometastatic esophageal squamous cell carcinoma: a propensity score matching and landmark analyses. Radiother Oncol 2021; 164: 236-244
• 19 Shi Z, Zhu X, Ruan C. et al. Evaluation of concurrent chemoradiotherapy for survival outcomes in patients with synchronous oligometastatic esophageal squamous cell carcinoma. JAMA Netw Open 2022; 5 (12) e2244619
• 20 Kroese TE, van Laarhoven HWM, Nilsson M. et al. Definition of oligometastatic esophagogastric cancer and impact of local oligometastasis-directed treatment: a systematic review and meta-analysis. Eur J Cancer 2022; 166: 254-269
• 21 Ji J, Liu Y, Bao Y, Men Y, Wang J, Hui Z. Effects of local treatment in combination with systemic therapy for advanced esophageal cancer: a systematic review and meta-analysis. Adv Radiat Oncol 2024; 9 (07) 101522
• 22 Liu Q, Zhu Z, Chen Y. et al. Phase 2 study of stereotactic body radiation therapy for patients with oligometastatic esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2020; 108 (03) 707-715
• 23 Zhao W, Ke S, Cai X. et al. Radiotherapy plus camrelizumab and irinotecan for oligometastatic esophageal squamous cell carcinoma patients after first-line immunotherapy plus chemotherapy failure: an open-label, single-arm, phase II trial. Radiother Oncol 2023; 184: 109679
• 24 Schizas D, Mylonas KS, Kapsampelis P. et al. Patients undergoing surgery for oligometastatic oesophageal cancer survive for more than 2 years: bootstrapping systematic review data. Interact Cardiovasc Thorac Surg 2020; 31 (03) 299-304
• 25 Smyth EC, Lagergren J, Fitzgerald RC. et al. Oesophageal cancer. Nat Rev Dis Primers 2017; 3: 17048
• 26 Liu Q, Chen J, Lin Y. et al. Systemic therapy with or without local intervention for oligometastatic oesophageal squamous cell carcinoma (ESO-Shanghai 13): an open-label, randomised, phase 2 trial. Lancet Gastroenterol Hepatol 2024; 9 (01) 45-55
• 27 Guidelines With Evidence Blocks. . Stomach. NCCN. Accessed September 10, 2024 at: https://www.nccn.org/guidelines/guidelines-with-evidence-blocks
• 28 Glimelius B, Ekström K, Hoffman K. et al. Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 1997; 8 (02) 163-168
• 29 Wagner AD, Syn NL, Moehler M. et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017; 8 (08) CD004064
• 30 Then EO, Grantham T, Deda X, Ramachandran R, Gaduputi V. Metastatic gastric cancer to the colon. World J Oncol 2021; 12 (04) 127-131
• 31 Al-Batran SE, Homann N, Pauligk C. et al. Effect of neoadjuvant chemotherapy followed by surgical resection on survival in patients with limited metastatic gastric or gastroesophageal junction cancer: The AIO-FLOT3 Trial. JAMA Oncol 2017; 3 (09) 1237-1244
• 32 Sano T, Coit DG, Kim HH. et al. Proposal of a new stage grouping of gastric cancer for TNM classification: International Gastric Cancer Association staging project. Gastric Cancer 2017; 20 (02) 217-225
• 33 Japanese Gastric Cancer Association. Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition). Gastric Cancer 2023; 26 (01) 1-25
• 34 Fujitani K, Yang HK, Mizusawa J. et al; REGATTA Study Investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016; 17 (03) 309-318
• 35 Cui Y, Yu Y, Zheng S. et al. Does resection after neoadjuvant chemotherapy of docetaxel, oxaliplatin, and S-1 (DOS regimen) benefit for gastric cancer patients with single non-curable factor? a multicenter, prospective cohort study (Neo-REGATTA). BMC Cancer 2023; 23 (01) 308
• 36 Study Details | Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction | ClinicalTrials.gov. Accessed September 10, 2024 at: https://clinicaltrials.gov/study/NCT02578368
• 37 Wang Y, Yu YY, Li W. et al. A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemother Pharmacol 2014; 73 (06) 1155-1161
• 38 Kodera Y, Ito S, Mochizuki Y. et al; Chubu Clinical Oncology Group. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study). Eur J Surg Oncol 2009; 35 (11) 1158-1163
• 39 Kodera Y, Ito S, Mochizuki Y. et al. Long-term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer 2012; 15 (03) 335-337
• 40 Markar SR, Mikhail S, Malietzis G. et al. Influence of surgical resection of hepatic metastases from gastric adenocarcinoma on long-term survival: systematic review and pooled analysis. Ann Surg 2016; 263 (06) 1092-1101
• 41 Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S. Pancreatic adenocarcinoma: improving prevention and survivorship. Am Soc Clin Oncol Educ Book 2017; 37 (37) 301-310
• 42 Conroy T, Desseigne F, Ychou M. et al; Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364 (19) 1817-1825
• 43 Golan T, Hammel P, Reni M. et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med 2019; 381 (04) 317-327
• 44 Marabelle A, Le DT, Ascierto PA. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the Phase II KEYNOTE-158 study. J Clin Oncol 2020; 38 (01) 1-10
• 45 Wu L, Zhu L, Xu K. et al. Clinical significance of site-specific metastases in pancreatic cancer: a study based on both clinical trial and real-world data. J Cancer 2021; 12 (06) 1715-1721
• 46 Ludmir EB, Sherry AD, Fellman BM. et al. Addition of metastasis-directed therapy to standard-of-care systemic therapy for oligometastatic pancreatic ductal adenocarcinoma (EXTEND): Results of a multicenter, randomized phase II trial. JCO 2024; 42 (03) 603
• 47 Elamir AM, Karalis JD, Sanford NN. et al. Ablative radiation therapy in oligometastatic pancreatic cancer to delay polyprogression, limit chemotherapy, and improve outcomes. Int J Radiat Oncol Biol Phys 2022; 114 (04) 792-802
• 48 Lee G, Kim DW, Oladeru OT. et al. Liver metastasis-directed ablative radiotherapy in pancreatic cancer offers prolonged time off systemic therapy in selected patients: data from a multi-institutional retrospective study. Pancreas 2021; 50 (05) 736-743
• 49 Timmer FEF, Geboers B, Nieuwenhuizen S. et al. Locoregional treatment of metastatic pancreatic cancer utilizing resection, ablation and embolization: a systematic review. Cancers (Basel) 2021; 13 (07) 1608
• 50 Menon G, Garikipati SC, Roy P. Cholangiocarcinoma. In: StatPearls. StatPearls Publishing; 2024. . Accessed September 11, 2024 at: http://www.ncbi.nlm.nih.gov/books/NBK560708/
• 51 Kelley RK, Ueno M, Yoo C. et al; KEYNOTE-966 Investigators. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2023; 401 (10391): 1853-1865
• 52 Oh DY, Ruth He A, Qin S. et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer. NEJM Evid 2022; 1 (08) a2200015
• 53 Valle J, Wasan H, Palmer DH. et al; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362 (14) 1273-1281
• 54 Addition of stereotactic body radiotherapy (SBRT) to systemic chemotherapy in locally advanced cholangiocarcinoma (CC) (ABC-07): Results from a randomized phase II trial. Journal of Clinical Oncology. Accessed November 1, 2024 at: https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.4006
• 55 Franzese C, Bonu ML, Comito T. et al. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity. J Cancer Res Clin Oncol 2020; 146 (09) 2289-2297
• 56 Morino K, Seo S, Yoh T. et al. Proposed definition for oligometastatic recurrence in biliary tract cancer based on results of locoregional treatment: a propensity-score-stratified analysis. Ann Surg Oncol 2020; 27 (06) 1908-1917
• 57 Sebastian NT, Tan Y, Miller ED. et al. Association of liver-directed local therapy with overall survival in adults with metastatic intrahepatic cholangiocarcinoma. JAMA Netw Open 2019; 2 (09) e1911154
• 58 Lotfollahzadeh S, Recio-Boiles A, Babiker HM. Liver cancer. In: StatPearls. StatPearls Publishing; 2024. . Accessed September 11, 2024 at: http://www.ncbi.nlm.nih.gov/books/NBK448337/
• 59 Ding J, Wen Z. Survival improvement and prognosis for hepatocellular carcinoma: analysis of the SEER database. BMC Cancer 2021; 21 (01) 1157
• 60 Finn RS, Qin S, Ikeda M. et al; IMbrave150 Investigators. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 2020; 382 (20) 1894-1905
• 61 Choi SH, Lee BM, Kim J, Kim DY, Seong J. Efficacy of stereotactic ablative radiotherapy in patients with oligometastatic hepatocellular carcinoma: a phase II study. J Hepatol 2024; 81 (01) 84-92
• 62 Chen YX, Yang P, Du SS. et al. Stereotactic body radiotherapy combined with sintilimab in patients with recurrent or oligometastatic hepatocellular carcinoma: a phase II clinical trial. World J Gastroenterol 2023; 29 (24) 3871-3882
• 63 Kim TH, Nam TK, Yoon SM, Kim TH, Choi YM, Seong J. Stereotactic ablative radiotherapy for oligometastatic hepatocellular carcinoma: a multi-institutional retrospective study (KROG 20-04). Cancers (Basel) 2022; 14 (23) 5848
• 64 Kim S, Lee J, Rim CH. Local treatment of hepatocellular carcinoma with oligometastases: a systematic review and meta-analysis. Cancers (Basel) 2023; 15 (13) 3467
• 65 Wang J, Li S, Liu Y, Zhang C, Li H, Lai B. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: a population-based analysis. Cancer Med 2020; 9 (01) 361-373
• 66 Guidelines With Evidence Blocks. . Colon. NCCN. Accessed September 11, 2024 at: https://www.nccn.org/guidelines/guidelines-with-evidence-blocks
• 67 Van Cutsem E, Köhne CH, Láng I. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29 (15) 2011-2019
• 68 Lenz HJ, Van Cutsem E, Luisa Limon M. et al. First-line nivolumab plus low-dose ipilimumab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: the Phase II CheckMate 142 Study. J Clin Oncol 2022; 40 (02) 161-170
• 69 Aloia TA, Vauthey JN, Loyer EM. et al. Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 2006; 141 (05) 460-466 , discussion 466–467
• 70 Kanas GP, Taylor A, Primrose JN. et al. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012; 4: 283-301
• 71 Boudjema K, Locher C, Sabbagh C. et al; METASYNC Study group. Simultaneous versus delayed resection for initially resectable synchronous colorectal cancer liver metastases: a prospective, open-label, randomized, controlled trial. Ann Surg 2021; 273 (01) 49-56
• 72 Tanis E, Nordlinger B, Mauer M. et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 2014; 50 (05) 912-919
• 73 Kobiela J, Spychalski P, Marvaso G. et al. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review. Crit Rev Oncol Hematol 2018; 129: 91-101
• 74 Comito T, Cozzi L, Clerici E. et al. Stereotactic ablative radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach. BMC Cancer 2014; 14 (01) 619
• 75 Sutera P, Kalash R, Clump DA. et al. Stereotactic ablative radiation therapy for unresectable colorectal oligometastases. Adv Radiat Oncol 2018; 4 (01) 57-62
• 76 Scorsetti M, Comito T, Tozzi A. et al. Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancer. J Cancer Res Clin Oncol 2015; 141 (03) 543-553
• 77 Cho JH, Kim S, Namgung M. et al. The prognostic importance of the number of metastases in pulmonary metastasectomy of colorectal cancer. World J Surg Oncol 2015; 13 (01) 222
• 78 Salah S, Watanabe K, Welter S. et al. Colorectal cancer pulmonary oligometastases: pooled analysis and construction of a clinical lung metastasectomy prognostic model. Ann Oncol 2012; 23 (10) 2649-2655
• 79 Treasure T, Farewell V, Macbeth F. et al; PulMiCC Trial Group. Pulmonary Metastasectomy versus Continued Active Monitoring in Colorectal Cancer (PulMiCC): a multicentre randomised clinical trial. Trials 2019; 20 (01) 718
• 80 Nicosia L, Franceschini D, Perrone-Congedi F. et al. A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study. Radiother Oncol 2022; 166: 92-99
• 81 Ferguson J, Alzahrani N, Zhao J. et al. Long term results of RFA to lung metastases from colorectal cancer in 157 patients. Eur J Surg Oncol 2015; 41 (05) 690-695
• 82 Franko J, Shi Q, Meyers JP. et al; Analysis and Research in Cancers of the Digestive System (ARCAD) Group. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 2016; 17 (12) 1709-1719
• 83 Cashin PH, Mahteme H, Spång N. et al. Cytoreductive surgery and intraperitoneal chemotherapy versus systemic chemotherapy for colorectal peritoneal metastases: a randomised trial. Eur J Cancer 2016; 53: 155-162
• 84 Quénet F, Elias D, Roca L. et al; UNICANCER-GI Group and BIG Renape Group. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2021; 22 (02) 256-266
• 85 Guren MG, Aagnes B, Nygård M, Dahl O, Møller B. Rising incidence and improved survival of anal squamous cell carcinoma in Norway, 1987-2016. Clin Colorectal Cancer 2019; 18 (01) e96-e103
• 86 Rao S, Sclafani F, Eng C. et al. International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAAct. J Clin Oncol 2020; 38 (22) 2510-2518
• 87 Holliday EB, Lester SC, Harmsen WS. et al. Extended-field chemoradiation therapy for definitive treatment of anal canal squamous cell carcinoma involving the para-aortic lymph nodes. Int J Radiat Oncol Biol Phys 2018; 102 (01) 102-108
• 88 Lo WM, Dogeas E, Etherington MS. et al. Long-term overall survival in patients undergoing liver resection for metastatic anal squamous cell carcinoma. J Surg Oncol 2024; 129 (03) 568-573
• 89 Pawlik TM, Gleisner AL, Bauer TW. et al. Liver-directed surgery for metastatic squamous cell carcinoma to the liver: results of a multi-center analysis. Ann Surg Oncol 2007; 14 (10) 2807-2816
• 90 Wind KL, Serup-Hansen E, Havelund BM. et al. Definitive therapy for squamous cell carcinoma of the anus with synchronous metastases - a report from the Danish Anal Cancer Group. Acta Oncol 2022; 61 (03) 321-327
• 91 Evesque L, Benezery K, Follana P. et al. Multimodal therapy of squamous cell carcinoma of the anus with distant metastasis: a single-institution experience. Dis Colon Rectum 2017; 60 (08) 785-791
• 92 Eng C, Chang GJ, You YN. et al. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. Oncotarget 2014; 5 (22) 11133-11142
• 93 Study Details | Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT04248452
• 94 Study Details | Surgical Resection Plus Chemotherapy Versus Chemotherapy Alone in Oligometastatic Stage IV Gastric Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT03042169
• 95 Study Details | Chemotherapy Alone Versus Surgery Plus Chemotherapy for Distal Gastric Cancer With One Non-curable Factor | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT03399253
• 96 Study Details | Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer | ClinicalTrials.gov. Accessed September 10, 2024 at: https://clinicaltrials.gov/study/NCT03161522
• 97 Study Details | A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT04512417
• 98 Study Details | PD-1 Antibody Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Limited Metastatic Gastric Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT04510064
• 99 Jo P, Ghadimi M, Pelzer U. et al. METAPANC, intensified treatment in patients with oligometastatic pancreatic cancer: Multimodal surgical treatment versus systemic chemotherapy alone—A prospective randomized controlled multicenter phase III trial. JCO 2024; 42 (16) TPS4207-TPS4207
• 100 Study Details | Chemotherapy and Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas | ClinicalTrials.gov. Accessed September 11, 2024 at: https://www.clinicaltrials.gov/study/NCT04617457
• 101 Study Details | Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT04975516
• 102 Wei M, Shi S, Hua J, Xu J, Yu X. Chinese Study Group for Pancreatic Cancer (CSPAC). Simultaneous resection of the primary tumour and liver metastases after conversion chemotherapy versus standard therapy in pancreatic cancer with liver oligometastasis: protocol of a multicentre, prospective, randomised phase III control trial (CSPAC-1). BMJ Open 2019; 9 (12) e033452
• 103 Study Details | Surgery for Liver Metastases From PDAC | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT05271110
• 104 Study Details | Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC | ClinicalTrials.gov. Accessed September 11, 2024 at: https://www.clinicaltrials.gov/study/NCT05917431
• 105 Study Details | Chemotherapy and Maximal Tumor Debulking of Multi-organ Colorectal Cancer Metastases | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/nct01792934
• 106 Study Details | Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study | ClinicalTrials.gov. Accessed September 11, 2024. https://www.clinicaltrials.gov/study/NCT05673148
• 107 Study Details | COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation | ClinicalTrials.gov. Accessed September 11, 2024 at: https://www.clinicaltrials.gov/study/NCT03088150
• 108 Study Details | Comparison of Hepatectomy and Local Ablation for Resectable Synchronous and Metachronous Colorectal Liver Metastasis | ClinicalTrials.gov. Accessed September 11, 2024 at: https://www.clinicaltrials.gov/study/NCT02886104
• 109 Study Details | Stereotactic Body Radiation Therapy vs. Microwave Ablation for Colorectal Cancer Patients With Metastatic Disease in the Liver | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT03654131
• 110 Study Details | Consolidative Radiotherapy Plus Maintenance Chemotherapy for Metastatic Colorectal Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/nct03142282
• 111 Study Details | COLLISION XL: Unresectable Colorectal Liver Metastases (3–5cm): Stereotactic Body Radiotherapy vs. Microwave Ablation | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT04081168
• 112 Study Details | CRT Versus Surgery for Retroperitoneal or Paraaortic Lymph Node Recurrence of CRC | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT03725254
• 113 Study Details | Liver Transplantation and Colorectal Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT01479608
• 114 Study Details | The Swedish Study of Liver Transplantation for Non-resectable Colorectal Cancer Metastases | ClinicalTrials.gov. Accessed September 11, 2024 at: https://www.clinicaltrials.gov/study/NCT04161092
• 115 Study Details | Liver Transplantation in Patients With Unresectable Colorectal Liver Metastases Treated by Chemotherapy | ClinicalTrials.gov. Accessed September 11, 2024 at: https://www.clinicaltrials.gov/study/NCT02597348
• 116 Study Details | RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer | ClinicalTrials.gov. Accessed September 11, 2024 at: https://clinicaltrials.gov/study/NCT05862051